{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:15:31Z","timestamp":1790748931481,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.amjmed.2014.06.015","type":"journal-article","created":{"date-parts":[[2014,6,19]],"date-time":"2014-06-19T22:20:50Z","timestamp":1403216450000},"page":"1127.e1-1127.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Zoledronic Acid in Osteoporosis Secondary to\u00a0Mastocytosis"],"prefix":"10.1016","volume":"127","author":[{"given":"Maurizio","family":"Rossini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Zanotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ombretta","family":"Viapiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Tripi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Idolazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Biondan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Orsolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Bonadonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvano","family":"Adami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2014.06.015_bib1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.iac.2014.01.011","article-title":"Bone involvement and osteoporosis in mastocytosis","volume":"34","author":"Rossini","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.amjmed.2014.06.015_bib2","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1136\/ard.2009.124511","article-title":"Systemic mastocytosis and bone involvement in a cohort of 75 patients","volume":"69","author":"Barete","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.amjmed.2014.06.015_bib3","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.bone.2011.07.004","article-title":"Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis","volume":"49","author":"Rossini","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.amjmed.2014.06.015_bib4","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1398-9995.2011.02780.x","article-title":"High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis","volume":"67","author":"van der Veer","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.amjmed.2014.06.015_bib5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bbadis.2010.12.014","article-title":"Mast cells and inflammation","volume":"1822","author":"Theoharides","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.amjmed.2014.06.015_bib6","doi-asserted-by":"crossref","first-page":"75 e71","DOI":"10.1016\/j.amjmed.2012.07.018","article-title":"Bone complications of mastocytosis: a link between clinical and biological characteristics","volume":"126","author":"Guillaume","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2014.06.015_bib7","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jaci.2013.06.019","article-title":"Serum levels of bone cytokines are increased in indolent systemic mastocytosis associated with osteopenia or osteoporosis","volume":"132","author":"Rabenhorst","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.amjmed.2014.06.015_bib8","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jaci.2013.12.007","article-title":"Serum levels of bone cytokines in indolent systemic mastocytosis associated with osteopenia or osteoporosis","volume":"133","author":"Rossini","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.amjmed.2014.06.015_bib9","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1007\/s00198-013-2305-x","article-title":"Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis","volume":"24","author":"Seitz","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.amjmed.2014.06.015_bib10","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.amjmed.2011.02.038","article-title":"Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis","volume":"124","author":"Laroche","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2014.06.015_bib11","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.amjmed.2014.06.015_bib12","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/rheumatology\/36.3.393","article-title":"The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis","volume":"36","author":"Marshall","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.amjmed.2014.06.015_bib13","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1359\/jbmr.2002.17.4.567","article-title":"Osteoporosis and bone marrow mastocytosis: dissociation of skeletal responses and mast cell activity during long-term bisphosphonate therapy","volume":"17","author":"Brumsen","year":"2002","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.amjmed.2014.06.015_bib14","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1136\/ard.2004.029116","article-title":"Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment","volume":"64","author":"Lim","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.amjmed.2014.06.015_bib15","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2014.06.015_bib16","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1056\/NEJMoa1204061","article-title":"Fracture risk and zoledronic acid therapy in men with osteoporosis","volume":"367","author":"Boonen","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjmed.2014.06.015_bib17","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/blood-2013-01-453183","article-title":"How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage)","volume":"121","author":"Pardanani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.amjmed.2014.06.015_bib18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.amjmed.2012.06.023","article-title":"Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday","volume":"126","author":"McClung","year":"2013","journal-title":"Am J Med"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934314005105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934314005105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:03:14Z","timestamp":1757581394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934314005105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0002934314005105"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2014.06.015","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Zoledronic Acid in Osteoporosis Secondary to\u00a0Mastocytosis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2014.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}